Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Durvalumab is a fully human immunoglobulin G1 kappa monoclonal antibody and immune checkpoint inhibitor that targets programmed death-ligand 1 (PD-L1). By blocking the interaction between PD-L1 on tumor cells and PD-1 or CD80 on T-cells, it enhances antitumor immune responses by increasing T-cell activation and delaying tumor growth. Durvalumab is primarily used in combination with platinum-containing chemotherapy for various cancers including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), and endometrial cancer. It is developed by AstraZeneca and marketed under the brand name Imfinzi[4][5][7].
- Brand names
- Imfinzi
- Other names
- durvalumabMEDI4736MEDI-4736MEDI 4736Imfinzi
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + chemotherapy.